Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides

A. Erdei, Adina Borbély, Anna Magyar, Edina Szűcs, F. Ötvös, Dávid Gombos, M. Al-Khrasani, Azzurra Stefanucci, Marilisa Pia Dimmito, Grazia Luisi, Adriano Mollica, S. Benyhe

Research output: Contribution to journalArticle

Abstract

The endogenous ligand nociceptin (N/OFQ) and a positively charged synthetic peptide RYYRIK are both selective for the nociceptin opioid receptor (NOPr). Despite their structural dissimilarity, N/OFQ and RYYRIK compete for the same binding site of NOP receptor possessing full and partial agonistic character, respectively. In the view of the message-address concept, hybrid peptide constructs were probed for the NOP receptor combining different regions of N/OFQ and RYYRIK related peptide sequences. Nine novel nociceptin- or Ac-RYYRIK-NH2 peptide variants or hybrid peptides were synthesized and characterized. Peptides P2 and P8 contain fragments of native N/OFQ. The other seven analogues (P1, P3-7, P9) are composed of Ac-RYYRIK-NH2 fragments and parts of the original nociceptin sequence. The analogues were characterized in receptor binding assays and G-protein activation experiments on rat brain membranes, as well as by electrically stimulated mouse vas deferens bioassay. In receptor binding assays ligands P2, P4, P6 (Ki 0.37 nM) and P7 showed higher affinity (Ki 0.65 nM, 0.6 nM, 0.37 nM and 0.44 nM, respectively) for NOP receptor than their parent compounds N/OFQ (Ki 2.8 nM) or Ac-RYYRIK-NH2 (Ki 4.2 nM). In [35S]GTPγS binding experiments P2 and P3 behaved as full agonists. The other variants exhibited partial agonist properties characterized by submaximal stimulatory effects. In mouse vas deferens bioassay only P2 showed agonist activity. P4, P5, P6 inhibited the biological activity of N/OFQ more effectively than the NOP receptor selective antagonist JTC-801. In summary, hybrid peptides P4, P5 and P6 proved to be NOP receptor partial agonists even antagonists, while P2 peptide retained the full agonist property.

LanguageEnglish
Pages106-113
Number of pages8
JournalPeptides
Volume112
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Pharmacology
Peptides
Vas Deferens
Bioassay
Biological Assay
Assays
Ligands
Opioid Receptors
Bioactivity
GTP-Binding Proteins
Rats
Brain
Carrier Proteins
Experiments
Chemical activation
Binding Sites
nociceptin
Membranes
P2 peptide

Keywords

  • Bivalent ligands
  • G-protein activation
  • Hybrid peptides
  • Mouse vas deferens bioassay
  • Nociceptin
  • Opioid receptor
  • Receptor binding

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Cellular and Molecular Neuroscience

Cite this

Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides. / Erdei, A.; Borbély, Adina; Magyar, Anna; Szűcs, Edina; Ötvös, F.; Gombos, Dávid; Al-Khrasani, M.; Stefanucci, Azzurra; Dimmito, Marilisa Pia; Luisi, Grazia; Mollica, Adriano; Benyhe, S.

In: Peptides, Vol. 112, 01.02.2019, p. 106-113.

Research output: Contribution to journalArticle

Erdei, A. ; Borbély, Adina ; Magyar, Anna ; Szűcs, Edina ; Ötvös, F. ; Gombos, Dávid ; Al-Khrasani, M. ; Stefanucci, Azzurra ; Dimmito, Marilisa Pia ; Luisi, Grazia ; Mollica, Adriano ; Benyhe, S. / Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides. In: Peptides. 2019 ; Vol. 112. pp. 106-113.
@article{67f5998318264f8c88e087270e685c58,
title = "Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides",
abstract = "The endogenous ligand nociceptin (N/OFQ) and a positively charged synthetic peptide RYYRIK are both selective for the nociceptin opioid receptor (NOPr). Despite their structural dissimilarity, N/OFQ and RYYRIK compete for the same binding site of NOP receptor possessing full and partial agonistic character, respectively. In the view of the message-address concept, hybrid peptide constructs were probed for the NOP receptor combining different regions of N/OFQ and RYYRIK related peptide sequences. Nine novel nociceptin- or Ac-RYYRIK-NH2 peptide variants or hybrid peptides were synthesized and characterized. Peptides P2 and P8 contain fragments of native N/OFQ. The other seven analogues (P1, P3-7, P9) are composed of Ac-RYYRIK-NH2 fragments and parts of the original nociceptin sequence. The analogues were characterized in receptor binding assays and G-protein activation experiments on rat brain membranes, as well as by electrically stimulated mouse vas deferens bioassay. In receptor binding assays ligands P2, P4, P6 (Ki 0.37 nM) and P7 showed higher affinity (Ki 0.65 nM, 0.6 nM, 0.37 nM and 0.44 nM, respectively) for NOP receptor than their parent compounds N/OFQ (Ki 2.8 nM) or Ac-RYYRIK-NH2 (Ki 4.2 nM). In [35S]GTPγS binding experiments P2 and P3 behaved as full agonists. The other variants exhibited partial agonist properties characterized by submaximal stimulatory effects. In mouse vas deferens bioassay only P2 showed agonist activity. P4, P5, P6 inhibited the biological activity of N/OFQ more effectively than the NOP receptor selective antagonist JTC-801. In summary, hybrid peptides P4, P5 and P6 proved to be NOP receptor partial agonists even antagonists, while P2 peptide retained the full agonist property.",
keywords = "Bivalent ligands, G-protein activation, Hybrid peptides, Mouse vas deferens bioassay, Nociceptin, Opioid receptor, Receptor binding",
author = "A. Erdei and Adina Borb{\'e}ly and Anna Magyar and Edina Szűcs and F. {\"O}tv{\"o}s and D{\'a}vid Gombos and M. Al-Khrasani and Azzurra Stefanucci and Dimmito, {Marilisa Pia} and Grazia Luisi and Adriano Mollica and S. Benyhe",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.peptides.2018.11.010",
language = "English",
volume = "112",
pages = "106--113",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides

AU - Erdei, A.

AU - Borbély, Adina

AU - Magyar, Anna

AU - Szűcs, Edina

AU - Ötvös, F.

AU - Gombos, Dávid

AU - Al-Khrasani, M.

AU - Stefanucci, Azzurra

AU - Dimmito, Marilisa Pia

AU - Luisi, Grazia

AU - Mollica, Adriano

AU - Benyhe, S.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The endogenous ligand nociceptin (N/OFQ) and a positively charged synthetic peptide RYYRIK are both selective for the nociceptin opioid receptor (NOPr). Despite their structural dissimilarity, N/OFQ and RYYRIK compete for the same binding site of NOP receptor possessing full and partial agonistic character, respectively. In the view of the message-address concept, hybrid peptide constructs were probed for the NOP receptor combining different regions of N/OFQ and RYYRIK related peptide sequences. Nine novel nociceptin- or Ac-RYYRIK-NH2 peptide variants or hybrid peptides were synthesized and characterized. Peptides P2 and P8 contain fragments of native N/OFQ. The other seven analogues (P1, P3-7, P9) are composed of Ac-RYYRIK-NH2 fragments and parts of the original nociceptin sequence. The analogues were characterized in receptor binding assays and G-protein activation experiments on rat brain membranes, as well as by electrically stimulated mouse vas deferens bioassay. In receptor binding assays ligands P2, P4, P6 (Ki 0.37 nM) and P7 showed higher affinity (Ki 0.65 nM, 0.6 nM, 0.37 nM and 0.44 nM, respectively) for NOP receptor than their parent compounds N/OFQ (Ki 2.8 nM) or Ac-RYYRIK-NH2 (Ki 4.2 nM). In [35S]GTPγS binding experiments P2 and P3 behaved as full agonists. The other variants exhibited partial agonist properties characterized by submaximal stimulatory effects. In mouse vas deferens bioassay only P2 showed agonist activity. P4, P5, P6 inhibited the biological activity of N/OFQ more effectively than the NOP receptor selective antagonist JTC-801. In summary, hybrid peptides P4, P5 and P6 proved to be NOP receptor partial agonists even antagonists, while P2 peptide retained the full agonist property.

AB - The endogenous ligand nociceptin (N/OFQ) and a positively charged synthetic peptide RYYRIK are both selective for the nociceptin opioid receptor (NOPr). Despite their structural dissimilarity, N/OFQ and RYYRIK compete for the same binding site of NOP receptor possessing full and partial agonistic character, respectively. In the view of the message-address concept, hybrid peptide constructs were probed for the NOP receptor combining different regions of N/OFQ and RYYRIK related peptide sequences. Nine novel nociceptin- or Ac-RYYRIK-NH2 peptide variants or hybrid peptides were synthesized and characterized. Peptides P2 and P8 contain fragments of native N/OFQ. The other seven analogues (P1, P3-7, P9) are composed of Ac-RYYRIK-NH2 fragments and parts of the original nociceptin sequence. The analogues were characterized in receptor binding assays and G-protein activation experiments on rat brain membranes, as well as by electrically stimulated mouse vas deferens bioassay. In receptor binding assays ligands P2, P4, P6 (Ki 0.37 nM) and P7 showed higher affinity (Ki 0.65 nM, 0.6 nM, 0.37 nM and 0.44 nM, respectively) for NOP receptor than their parent compounds N/OFQ (Ki 2.8 nM) or Ac-RYYRIK-NH2 (Ki 4.2 nM). In [35S]GTPγS binding experiments P2 and P3 behaved as full agonists. The other variants exhibited partial agonist properties characterized by submaximal stimulatory effects. In mouse vas deferens bioassay only P2 showed agonist activity. P4, P5, P6 inhibited the biological activity of N/OFQ more effectively than the NOP receptor selective antagonist JTC-801. In summary, hybrid peptides P4, P5 and P6 proved to be NOP receptor partial agonists even antagonists, while P2 peptide retained the full agonist property.

KW - Bivalent ligands

KW - G-protein activation

KW - Hybrid peptides

KW - Mouse vas deferens bioassay

KW - Nociceptin

KW - Opioid receptor

KW - Receptor binding

UR - http://www.scopus.com/inward/record.url?scp=85058528294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058528294&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2018.11.010

DO - 10.1016/j.peptides.2018.11.010

M3 - Article

VL - 112

SP - 106

EP - 113

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -